Retatrutide is a triple receptor agonist (GLP-1, GIP, and glucagon) that produced 24.2% average weight loss over 48 weeks in Phase 2 trials

CrossRef Liver stiffness measurement-based risk score for predicting liver decompensation risk: a single-center retrospective Chinese study Yanqiu Li, Zihang Qiao, Jinze Li, Yongqi Li, Ying Feng, Xianbo Wang Clinical and Experimental Medicine .2025;[Epub] CrossRef Metabolomics and metabolites in cancer diagnosis and treatment Minyi Cai, Haiyan Liu, Chen Shao, Tingting Li, Jun Jin, Yahui Liang, Jinhu Wang, Ji Cao, Bo Yang, Qiaojun He, Xuejing Shao, Meidan Ying Molecular Biomedicine .2025;[Epub] CrossRef 14,240 View 312 Download 6 Web of Science Crossref Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L

Microglia mediated neuroinflammation in neurodegenerative diseases: a review on the cell signaling pathways involved in microglial activation
Azarboo A